Company / Cash & Equivalents
Liquidia Corp Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$190.7M
FY2025
5-year range
$57.5M / $190.7M
FY2021-FY2025
Trend
+8.0%
vs FY2024
Sector context
#93 of 209
Health Care
What the data says
At $191M, Liquidia Corp's cash & equivalents ranks #93 of 209 in the Health Care sector. Cash & Equivalents has fluctuated over the past 6 years, ranging from $57M in FY2021 to $191M in FY2025.
Based on SEC 10-K filings.
$191M in FY2025 with a 5-year CAGR of +23.9%.
Improved from $84M to $191M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +26.9%
- 5-Year CAGR
- +23.9%
- 10-Year CAGR
- -
Sector benchmark
#93 of 209 in Health CareTop 44% of 209This company $190.7M Sector average $696.0M
▼
-72.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +23.9%, indicating consistent growth.
- In FY2025, cash & equivalents increased 8.0% year-over-year.
- Ranks #93 out of 209 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.26 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $190.7M | +8.0% |
| FY2024 | $176.5M | +110.9% |
| FY2023 | $83.7M | -10.3% |
| FY2022 | $93.3M | +62.2% |
| FY2021 | $57.5M | -12.0% |
| FY2020 | $65.3M | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026